AeroLeads people directory · profile
Chris O'Donnell Email & Phone Number
Vice President - Business Development and Partner, Pfizer Ventures
at
Pfizer
2 work emails found
@pfizer.com
2 phones found area 860
LinkedIn matched
✓ Verified May 2026
4 data sources
Profile completeness 100%
Current company
Role
Vice President - Business Development and Partner, Pfizer Ventures
Location
United States, United States, United States
Who is Chris O'Donnell? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Chris O'Donnell is listed as Vice President - Business Development and Partner, Pfizer Ventures at Pfizer, based in United States, United States, United States. AeroLeads shows a work email signal at pfizer.com, phone signal with area code 860, and a matched LinkedIn profile for Chris O'Donnell.
Chris O'Donnell previously worked as Member Board Of Directors at Arrakis Therapeutics and Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation at Pfizer. Chris O'Donnell holds Post Doc, Organic Chemistry from Uc Irvine.
Company email context
Email format at Pfizer
This section adds company-level context without repeating Chris O'Donnell's masked contact details.
{first_initial}{last}@pfizer.com
79% confidence
AeroLeads found 2 current-domain work email signals for Chris O'Donnell. Compare company email patterns before reaching out.
Profile bio
About Chris O'Donnell
I obtained a B.S. in Chemistry from the University of Illinois in Urbana/Champaign and a Ph.D. in Organic Chemistry from the University of Wisconsin, Madison under the direction of Professor Steven D. Burke. As an NIH pre-doctoral fellow, my thesis work focused on the design and synthesis of unnatural ionophores. I then joined the group of Professor Larry E. Overman at the University of California-Irvine as an American Cancer Society postdoctoral fellow where I completed the total synthesis of gelsemine. I joined Pfizer in 1999 as a medicinal chemist in the Neuroscience Medicinal Chemistry group and worked in the areas of addiction, cognition, psychosis, Alzheimer ’s disease, and bipolar. As a scientist, project leader, and manager in these areas, I have led projects to the nomination of several clinical candidates, and my efforts were instrumental to the discovery of clinical candidates in the following programs: a7 nAChR agonist, GABAA inverse agonist, SERT/5-HT2A antagonist, AMPA PAM, the PDE2 inhibitor, GSM, and a4b2 nAChR partial agonist. In 2010, I built the Antibody Drug Conjugate chemistry group focused on oncology. My team and I have nominated fourteen conjugates for clinical development, 6 of which use proprietary linker/payloads from two different MOA classes and two that utilizes a novel site-specific conjugation methodology. Presently, seven of these conjugates have entered clinical trials and three are still in active development with the most advanced in Ph II clinical trials.In 2017, I created the Applied Synthesis Technologies group and built six new groups focusing on DNA encoded libraries, nano-scale PMC and HTE, rxn opt, photo-redox, flow and biocatalysis. I'm an author on >50 publications, inventor on over 20 patents and have given over 30 podium presentations. In 2018, I joined Pfizer Ventures.
Listed skills include Medicinal Chemistry, Drug Discovery, Pharmaceutical Industry, Biopharmaceuticals, and 20 others.
Current workplace
Chris O'Donnell's current company
Company context helps verify the profile and gives searchers a useful next step.
30 roles
Chris O'Donnell work experience
A career timeline built from the work history available for this profile.
Member Board Of Directors
Current
Dec 2021 - Present
Vice President - Business Development And Partner, Pfizer Ventures
Current
May 2022 - Present
Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation
Current
Jul 2020 - Present
Executive Director, External Sciences & Innovation & Principal, Pfizer Ventures
I am responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. My focus will be on early stage biotechnology companies that are developing new therapeutics to treat diseases in Oncology, Neuroscience, Inflammation and Immunology, Internal Medicine and Rare Diseases.
Mar 2018 - Jun 2020
Executive Director, Applied Synthesis Technology
- Built a team of synthetic chemists focused on new technologies to accelerate the discovery and development of new molecules from the mg to kg scale from Lead Development to First in Human clinical studies.
- Built six new groups focused on biocatalysis, photo-redox, flow, reaction optimization, parallel medicinal chemistry and DNA encoded libraries. Integrated these technologies into synthetic management team strategies..
- Designed the strategy to build Pfizer’s proprietary DNA encoded library for screening against new targets.
- Leader of the Joint Steering Committee for both the HitGen and TSRI collaborations. At the end of 2017, 5 libraries with over 2 billion compounds were prepared and 3 of the 5 TSRI proposal advanced to attempting the.
- Built the strategy to invest our Science and Technology budget.
Nov 2016 - Mar 2018
Executive Director, Oncology Medicinal Chemistry
- Built the strategy and executed the tactics of the Antibody Drug Conjugate medicinal chemistry group, Natural Products group and devised the strategy around targeted nanoparticles to deliver novel immune-oncology.
- In addition, maintained all of the associated responsibilities of my Senior Director role below.My group focused on the discovery of novel cytotoxins, linkers and site specific conjugation methods for the discovery of.
Sep 2015 - Dec 2016
Senior Director, Oncology Medicinal Chemistry
- Developed the strategy and designed the organizational structure and developed a new medicinal chemistry group to delivery novel payloads, linkers and antibody drug conjugates for the treatment of cancer.
- 6 conjugates were advanced to clinical trial (5T4, Notch3, Trop2, EFNA4a, PTK7, GD3), 4 using proprietary payloads and site-specific linker technology developed by my team, for which I am an co-inventor of these.
- Member of Oncology Leadership team managing a portfolio of over 20 small molecule and ADC programs.
- Co-Leader of the ADC Strategy Team. Responsible for building networks with Oncology Research Unit located in Pearl River, NY and La Jolla, CA, Global Biotherapeutics Technologies group in Cambridge, MA, Rinat in San.
- Developed key partnerships with Centers for Therapeutic Innovation (CTI) in Cambridge, MA, New York, NY and San Francisco, CA.
- Chemistry point of contact for evaluating business development opportunities with outside partners. Established 4 key partners with the Oncology Research Unit (ORU) (Seattle Genetics, StemCentrx, Cytomx, Philogen)..
Jan 2010 - Sep 2015
Senior Director, Neuroscience Medicinal Chemistry
- Developed the strategy and managed a portfolio of projects targeting Schizophrenia, Alzheimer’s Disease, Bipolar Disorder and Autism. During my leadership, 3 programs advanced from the exploratory stage to lead.
- Responsible for organizational design and talent selection related to the Wyeth merge. Responsible for project assessment of the Wyeth portfolio and transfer of two clinical assets and 2 preclinical projects into our.
- Led AB/CNS Medicinal Chemistry’s efforts to focus on improving our synthetic talent, recruiting new talent, creating new synthesis roles as well as new design roles especially around data analysis/chemoinformatics.
- As a member of the Neuroscience (NS) Portfolio Management Team, responsible for the strategic management and resource decisions for the NS portfolio (~20 programs ranging from exploratory to clinical candidate.
Jan 2009 - Nov 2010
Director, Neuroscience Medicinal Chemistry
- Drove the medicinal chemistry design and synthesis strategy for a portfolio of projects targeting diseases such as Schizophrenia (AMPA), Alzheimer’s Disease (GSM), Bipolar Disorder (CK1) and Autism (NRI/5HT1a). Three.
- Led the Groton chemistry group’s efforts toward improving excellence in synthesis which resulted in dramatically improved infrastructure, education of our staff, communication of results and higher quality data sets.
- As a member of the Neuroscience Portfolio Management Team, responsible for the strategic management and resource decisions for the NS portfolio (~20 programs ranging from exploratory to clinical candidate selection)..
- Responsible for talent evaluation and project transition to the Groton Site upon the Ann Arbor site closure and for the transition of 3 PIs from Ann Arbor to the successful start up of group in Groton.
Jan 2007 - Dec 2008
Associate Director, Neuroscience Medicinal Chemistry
- Responsible for managing a group of 3 PhD laboratories along with my own laboratory. Each laboratory unit consisted of 1 PhD chemist and 2 MS/BS chemists. Total group size was 12 internal FTEs and 7 external FTEs.
- Drove three projects for the treatment of Depression (SRI+), ADHD (H3) and Schizophrenia (AMPA). Two clinical candidates emerged from these efforts that were discovered in my laboratory (AMPA & SRI+).
- Also served as the discovery team rep on the ADHD development team which drove multiple compounds toward clinical POC.
- As a member of the CNS Portfolio Management Team, managed a portfolio of 15 projects for the CNS group.
Jan 2006 - Dec 2007
Project Team Lead, Neuroscience Medicinal Chemistry
Led a muti-disciplinary team (Chemistry, Biology, PDM, Safety ~ 30 FTEs) targeting novel programs for the treatment of depression. Our team’s efforts resulted in identification of 4 clinical candidates.
Jan 2006 - Dec 2007
Senior Principal Scientist, Cns Medicinal Chemistry
- CNS Medicinal Chemistry, Pfizer Inc., Groton CT
- Design and synthesis of biologically active compounds for the treatment of neurological disorders.
- Inventor of four clinical candidates that advanced to human clinical trials (SRI+ - 3 candidates), 7 nAChR agonists).
- Supervised 2 research associates, one summer intern and 4 outsourcing FTE’s.
- Steering Committee Member and Chemical Working Group Leader for the ChemBridge File Enrichment collaboration.
Jan 2004 - Dec 2006
Senior Research Scientist, Cns Medicinal Chemistry
- CNS Medicinal Chemistry, Pfizer Inc., Groton CT
- Design and synthesis of biologically active compounds for the treatment of neurological disorders.
- Supervised 2 research associates, one summer intern and 3 outsourcing FTE’s.
- Contributed to the discovery of two clinical candidates (GABAa and the 42 nAChR backup to varenicline).
- Chemical Working Group Leader for the file enrichment collaboration with ChemBridge.
Jan 2001 - Dec 2004
Research Scientist, Cns Medicinal Chemistry
- CNS Medicinal Chemistry, Pfizer Inc, Groton, CT
- Design and synthesis of biologically active compounds for the treatment of neurological disorders. Supervised 2 research associates.
- Inventor of the alpha 7 nAChR agonist clinical candidate, CP-810,123).
Jul 1999 - Dec 2001
Technical Advisory Board
Current
Feb 2022 - Present
Member Board Of Directors
Current
Apr 2022 - Present
Board Observer
Current
Dec 2021 - Present
Board Of Directors
Current
Aug 2021 - Present
Board Of Directors
Current
May 2019 - Present
Board Of Directors
Current
May 2019 - Present
Board Of Directors
Current
Jan 2021 - Present
Board Observer
Nov 2018 - Jan 2021
Board Of Directors
Adapsyn Biosciences
Apr 2019 - Jun 2024
Member Board Of Directors
Mar 2021 - Oct 2021
Board Observer
Apr 2019 - Dec 2020
Board Of Directors
May 2019 - Aug 2020
Board Observer
Nov 2018 - May 2019
Board Observer
Petra Pharma Corporation
Jan 2019 - Mar 2020
Board Observer
Nov 2018 - Jul 2019
3 education records
Chris O'Donnell education
Post Doc, Organic Chemistry
Uc Irvine
Phd, Organic Chemistry
University Of Wisconsin-Madison
Bachelor Of Science - Bs, Organic Chemistry
University Of Illinois Urbana-Champaign
FAQ
Frequently asked questions about Chris O'Donnell
Quick answers generated from the profile data available on this page.
What company does Chris O'Donnell work for?
Chris O'Donnell works for Pfizer.
What is Chris O'Donnell's role at Pfizer?
Chris O'Donnell is listed as Vice President - Business Development and Partner, Pfizer Ventures at Pfizer.
What is Chris O'Donnell's email address?
AeroLeads has found 2 work email signals at @pfizer.com for Chris O'Donnell at Pfizer.
What is Chris O'Donnell's phone number?
AeroLeads has found 2 phone signal(s) with area code 860 for Chris O'Donnell at Pfizer.
Where is Chris O'Donnell based?
Chris O'Donnell is based in United States, United States, United States while working with Pfizer.
What companies has Chris O'Donnell worked for?
Chris O'Donnell has worked for Pfizer, Arrakis Therapeutics, Pyxis Oncology, Triana Biomedicines, and Kestrel Therapeutics.
How can I contact Chris O'Donnell?
You can use AeroLeads to view verified contact signals for Chris O'Donnell at Pfizer, including work email, phone, and LinkedIn data when available.
What schools did Chris O'Donnell attend?
Chris O'Donnell holds Post Doc, Organic Chemistry from Uc Irvine.
What skills is Chris O'Donnell known for?
Chris O'Donnell is listed with skills including Medicinal Chemistry, Drug Discovery, Pharmaceutical Industry, Biopharmaceuticals, Oncology, Drug Development, Drug Design, and Lifesciences.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial